Skip to content

Berobenatide dosage and evidence

Written by Reviewed Sep 2026

Limited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, none stating how many people.1 reported

The short answer

Berobenatide is a very long-lasting GLP-1 shot, built to be given once a month. It stays in the body about 15 days. Pfizer got it when it bought Metsera, and it is heading into ten large final-stage studies.

Evidence grade for Berobenatide: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 3 completed trials, none stating how many people. A grade counts how much has been done to people, not whether it works.

People given it
0
Human studies
3
Found nothing
0

Dose

No human dose established

Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.

3 completed trials, 0 people given it

1 effects reported, 1 wanted, by people using it, not a trial

Goal pages: Fat loss and metabolism

In plain English

In plain English, from Aaron

This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.

Berobenatide is a GLP-1 shot built to last. It stays in the body about 15 days, so it can be given once a month. Pfizer got it when it bought Metsera. It is not approved.

What people take it for

  • One shot a month instead of one a week.
  • Keeping weight off after the first loss.

What studies in people showed

On weekly shots, the best dose took off 14.1 percent more weight than a dummy shot at 28 weeks. In another study, people started weekly and then moved to one shot a month. At week 28 they had lost 10 to 12.3 percent more than the dummy group. Weight was still falling. These numbers came from company releases, not published papers.

What people report

Reports, not study results

The good

  • In the company reports on this page, weight kept coming off on the monthly shot, with no plateau at 28 weeks.

The bad

  • The reports on this page do not list side effects, and we have not collected user reports on this one yet.

Where these come from: The good line is from the study record and company releases on this page. We have not collected forum or user reports for this drug yet.

My bottom line

Monthly is handy. But these are company numbers from mid-stage studies. Wait for the big studies and a real prescription.

An opinion, not a finding. I am a coach, not a doctor.

What it has been measured to do

Measured in people

Goals Berobenatide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.

35 of the 36 indexed goals have no study of any kind behind Berobenatide

No study in people, animals or cells on this page reports a result for these. That does not prove Berobenatide does nothing for them. It does mean anything you have heard about Berobenatide and one of these did not come from a study cited here.

Feeling less hungryLosing fat specificallyKeeping or building muscleGetting strongerLasting longer, staminaBlood sugar and insulinCholesterol and blood fatsLiver fat and liver healthCell energy and mitochondriaInflammationJoint and knee painTendon, ligament and injury healingWound and skin healingGut and digestionBone strengthImmune functionPainEyes and visionMemory and thinkingMood and anxietySleepEnergy and fatigueSkin, wrinkles and elasticityHairTanning and pigmentationGrowth hormone and IGF-1Testosterone and male hormonesLibido and sexual functionThyroidBlood pressureHeart attacks and strokesKidney functionLiving longerCancer and tumoursBiological age markers
Show full evidence

What is Berobenatide?

Berobenatide is a very long-lasting GLP-1 shot, built to be given once a month. It stays in the body about 15 days. Pfizer got it when it bought Metsera, and it is heading into ten large final-stage studies.

Berobenatide is an experimental GLP-1 drug. It is built to stick to albumin, a protein in the blood, which makes it last about 360 hours, or 15 days. Weekly shots took off up to 14.1 percent more weight than a dummy shot at 28 weeks, in a study called VESPER-1. In VESPER-3, people started on weekly shots, then switched to one shot a month, and they kept losing weight. At week 28 they had lost 10 to 12.3 percent more than the dummy group, with no sign of levelling off. Pfizer bought the maker, Metsera, in late 2025 and planned large final-stage studies for 2026.

How does Berobenatide work?

It turns on the GLP-1 signal, which cuts appetite and slows how fast food leaves the stomach. It lasts so long that people can start with weekly shots, then move to monthly ones.

The evidence, in charts

Fig. 1a · how many people

3studies in people cited, but none says how many people took part

number of people not stated

We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.

We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.

Fig. 1b · evidence mix

All 3 sources here are studies in people.

03 sources
  • Study in people · done in people3100%

Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.

Fig. 2 · evidence over time

Sources here come from just two years, 2025 and 2026.

Too few different years on this page to draw a timeline.

Fig. 3 · legal status at a glance

Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.

Fig. 4 · how much does what

Nobody has tested different amounts in people

This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.

Waiting on a study nobody has runMaking one takes a study that gives different amounts to different groups of people and compares them. Nobody has paid for that for this compound.

Fig. 5 · what the molecule is

Kind of compound
Peptide
Molecule weight
Not disclosed
Half-life
About 15 daysVery long, weeks+
Chain length
None on file

No amino acid sequence is on file for Berobenatide, so none is drawn rather than guessed from a name.

The studies we cite

  • Study in people2026
    VESPER-3: monthly maintenance dosing of MET-097i

    Switching to a monthly shot did not stall the weight loss. People started on weekly berobenatide, then moved to one injection a month. By week 28 they had lost about 10% to 12% more of their body weight than the dummy group, and the line was still falling. This is a mid-stage trial, and the figures reached the public before any journal published them. No final-stage trial has confirmed the monthly schedule yet.

    10.0% and 12.3% placebo-adjusted loss at week 28 after switching to monthly dosing.

    NCT06973720 ClinicalTrials.gov NCT06973720
  • Study in people2026
    Pfizer's ultra-long-acting injectable GLP-1 RA shows robust weight loss

    Weight was still coming off at the end of the study rather than levelling out. On a monthly injection, people kept losing through week 28 with no sign of a plateau. That matters, because most weight drugs flatten out well before this point. Here is the catch. This came from Pfizer's own announcement, not from a published paper, so nobody outside the company has checked the numbers underneath it.

    Monthly regimen continued to reduce weight with no plateau at 28 weeks.

    Source Pfizer press release
  • Study in people2025
    Metsera reports positive Phase 2b results for MET-097i

    The weekly version took off weight in the same range as the injections people already use. At 28 weeks the best dose removed about 14% more body weight than a dummy injection. This was the mid-stage study that sent the drug into final-stage testing. The figures came from a company press release rather than a journal, so the detail behind them has not been reviewed by anyone independent.

    Up to 14.1% placebo-adjusted weight loss at 28 weeks on weekly dosing.

    Source Metsera press release

Where to buy Berobenatide

No seller we track lists Berobenatide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded

Common questions

Has Berobenatide been tested in people?

Yes. 0 people given it across 3 completed trials cited here, 0 of which found nothing. Berobenatide is a very long-lasting GLP-1 shot, built to be given once a month. It stays in the body about 15 days. Pfizer got it when it bought Metsera, and it is heading into ten large final-stage studies.

What is the Berobenatide dosage?

No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 3 completed trials, 0 people given it

Is Berobenatide FDA-approved?

Investigational; final-stage studies planned for 2026

Why does a monthly GLP-1 matter?

Fewer shots and steadier drug levels could help people stay on it. A monthly shot is also being tested as a way to keep weight off after the first loss.

Is berobenatide the same as semaglutide?

No. Both turn on the GLP-1 signal, but berobenatide is a different molecule. It lasts about twice as long in the body and is built for monthly shots.

Latest reading on Berobenatide

Blog posts about Berobenatide, newest first.

Related compounds

SemaglutideMariTideAmycretinEcnoglutide